Fate Therapeutics Inc (FATE)
3.91
-0.23
(-5.56%)
USD |
NASDAQ |
May 17, 16:00
3.91
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Cash from Operations (Quarterly): -33.35M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -33.35M |
December 31, 2023 | -36.64M |
September 30, 2023 | -38.27M |
June 30, 2023 | -28.49M |
March 31, 2023 | -28.86M |
December 31, 2022 | -75.39M |
September 30, 2022 | -55.05M |
June 30, 2022 | -53.16M |
March 31, 2022 | -64.61M |
December 31, 2021 | -70.29M |
September 30, 2021 | -33.38M |
June 30, 2021 | -32.11M |
March 31, 2021 | -27.10M |
December 31, 2020 | -20.66M |
September 30, 2020 | -30.73M |
June 30, 2020 | 38.84M |
March 31, 2020 | -26.67M |
December 31, 2019 | -25.54M |
September 30, 2019 | -19.84M |
June 30, 2019 | -20.31M |
March 31, 2019 | -17.49M |
December 31, 2018 | -11.02M |
September 30, 2018 | -3.556M |
Date | Value |
---|---|
June 30, 2018 | -11.52M |
March 31, 2018 | -12.55M |
December 31, 2017 | -10.72M |
September 30, 2017 | -9.769M |
June 30, 2017 | -8.872M |
March 31, 2017 | -7.455M |
December 31, 2016 | -7.551M |
September 30, 2016 | -7.516M |
June 30, 2016 | -7.504M |
March 31, 2016 | -7.252M |
December 31, 2015 | -6.97M |
September 30, 2015 | -7.131M |
June 30, 2015 | 2.079M |
March 31, 2015 | -6.375M |
December 31, 2014 | -6.154M |
September 30, 2014 | -5.521M |
June 30, 2014 | -5.489M |
March 31, 2014 | -5.255M |
December 31, 2013 | -4.578M |
September 30, 2013 | -3.472M |
June 30, 2013 | -3.39M |
March 31, 2013 | -3.933M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-75.39M
Minimum
Dec 2022
38.84M
Maximum
Jun 2020
-34.08M
Average
-31.42M
Median
Cash from Operations (Quarterly) Benchmarks
Amicus Therapeutics Inc | -29.70M |
Sarepta Therapeutics Inc | -242.08M |
ADMA Biologics Inc | -2.218M |
Ocular Therapeutix Inc | -33.89M |
Viking Therapeutics Inc | -6.134M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | 17.31M |
Cash from Financing (Quarterly) | 95.49M |
Free Cash Flow | -139.78M |
Free Cash Flow Per Share (Quarterly) | -0.3307 |
Free Cash Flow to Equity (Quarterly) | -33.44M |
Free Cash Flow Yield | -36.05% |